Literature DB >> 9624510

Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

C Segura1, M Salvadó, I Collado, J Chaves, A Coira.   

Abstract

The beta-lactamases in 154 clinical Mycobacterium tuberculosis strains were studied. Susceptibilities to beta-lactam antibiotics, their combination with clavulanate (2:1), and two fluoroquinolones were determined in 24 M. tuberculosis strains susceptible to antimycobacterial drugs and in nine multiresistant strains. All 154 M. tuberculosis isolates showed a single chromosomal beta-lactamase pattern (pI 4.9 and 5.1). M. tuberculosis beta-lactamase hydrolyzes cefotaxime with a maximum rate of 22.5 +/- 2.19 IU/liter (strain 1382). Neither amoxicillin, carbenicillin, cefotaxime, ceftriaxone, nor aztreonam was active alone. Except for aztreonam, beta-lactam combinations with clavulanate produced better antimycobacterial activity.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9624510      PMCID： PMC105638     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 2.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

3.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

4.  Preliminary investigation of Mycobacterium tuberculosis biovars.

Authors:  M C Roman; M J Sicilia
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

5.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Identification of Mycobacterium tuberculosis and Mycobacterium avium-M. intracellulare directly from primary BACTEC cultures by using acridinium-ester-labeled DNA probes.

Authors:  K D Evans; A S Nakasone; P A Sutherland; L M de la Maza; E M Peterson
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

7.  Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

Authors:  H F Chambers; D Moreau; D Yajko; C Miick; C Wagner; C Hackbarth; S Kocagöz; E Rosenberg; W K Hadley; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 8.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

9.  Bacteriophage types of Mycobacterium tuberculosis in the United States.

Authors:  W D Jones; R C Good; N J Thompson; G D Kelly
Journal:  Am Rev Respir Dis       Date:  1982-06

10.  Distribution and characterization of beta-lactamases of mycobacteria and related organisms.

Authors:  H H Kwon; H Tomioka; H Saito
Journal:  Tuber Lung Dis       Date:  1995-04
View more
  9 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Unusual conformation of the SxN motif in the crystal structure of penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2010-03-03       Impact factor: 5.469

5.  Genes required for intrinsic multidrug resistance in Mycobacterium avium.

Authors:  Julie S Philalay; Christine O Palermo; Kirsten A Hauge; Tige R Rustad; Gerard A Cangelosi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 6.  Reappraising the use of β-lactams to treat tuberculosis.

Authors:  Sebastian G Kurz; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

7.  Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Authors:  Jean-Emmanuel Hugonnet; Lee W Tremblay; Helena I Boshoff; Clifton E Barry; John S Blanchard
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

8.  2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.

Authors:  Albert B Jeon; Andrés Obregón-Henao; David F Ackart; Brendan K Podell; Juan M Belardinelli; Mary Jackson; Tuan V Nguyen; Meghan S Blackledge; Roberta J Melander; Christian Melander; Benjamin K Johnson; Robert B Abramovitch; Randall J Basaraba
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

9.  Management of Severe Gastrointestinal Tuberculosis with Injectable Antituberculous Drugs.

Authors:  Luciano Z Goldani; Camila O Spessatto; Daltro L Nunes; Juliana G Oliveira; Eliziane Takamatu; Carlos T Cerski; Helena A S Goldani
Journal:  Trop Med Health       Date:  2015-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.